Eptifibatide provides additional platelet inhibition in non–ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the platelet activity extinction in non–Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study

L’agrégation plaquettaire et ses inhibiteurs dans les syndromes coronariens aigus

Antiplatelet agents are the cornerstone therapy of acute coronary syndromes. In the setting of ST elevation myocardial infarction, antiplatelet therapy prevent the prothrombotic effect of reperfusion therapy including thrombolysis and primary percutaneous coronary intervention. In non ST-elevation acute coronary syndromes, antiplatelet therapy prevent s complete coronary thrombotic occlusion and therefore the occurrence of ST elevation myocardial infarction. Antiplatelet agent benefit is related to the patient's risk profile. It is well established that combined antiplatelet therapy is the most effective in high risk patients. Several important issues have to be faced including the identification of non responders, dose adjustment and the management of temporary interruption of antiplatelet agents in stable coronary artery disease patients.